Antalpha Announces Launch of Initial Public Offering 6-05-2025, 21:19

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

C.K. McWhorter Introduces Ultra-Elite Wellness Chateau Collection: Elevating Luxury Hospitality with Holistic Well-being 23-03-2024, 08:54